TORONTO, July 10, 2023 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “Company”) announces that, in connection with its creditor protection proceedings under the Companies’...
TORONTO, May 25, 2023 (GLOBE NEWSWIRE) -- As announced on January 26, 2023, Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) and its subsidiaries were granted creditor protection...
TORONTO, March 14, 2023 (GLOBE NEWSWIRE) -- On January 26, 2023, Acerus Pharmaceuticals Corporation and certain of its subsidiaries (collectively, “Acerus”) were granted protection pursuant to...
TORONTO, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX: ASP; OTCQB: ASPCF) today announced that the Company and its subsidiaries, Acerus...
TORONTO, Dec. 26, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX: ASP; OTCQB: ASPCF) today announced that Mr. Scott Leckie has resigned from the...
TORONTO, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX: ASP; OTCQB: ASPCF) today announced that it and its wholly-owned subsidiary, Acerus...
TORONTO, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX: ASP; OTCQB: ASPCF) today reported its financial results for the three and...
TORONTO, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX:ASP; OTCQB:ASPCF) today announced that it has amended the promissory note (the...
Ernst & Young Orenda Corporate Finance Inc. (“EY”) engaged as independent financial advisors TORONTO, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “Company” or...
TORONTO, Aug. 23, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX:ASP; OTCQB:ASPCF) today announced that Robert Motz has informed the Company of his...
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0.36 | 0.36 | 0.36 | 0 | 0 | CS |
4 | 0 | 0 | 0.36 | 0.36 | 0.36 | 0 | 0 | CS |
12 | 0 | 0 | 0.36 | 0.36 | 0.36 | 0 | 0 | CS |
26 | 0 | 0 | 0.36 | 0.36 | 0.36 | 0 | 0 | CS |
52 | 0 | 0 | 0.36 | 0.36 | 0.36 | 0 | 0 | CS |
156 | 0.325 | 928.571428571 | 0.035 | 5.67 | 0.025 | 17354 | 0.06918553 | CS |
260 | 0.29 | 414.285714286 | 0.07 | 5.67 | 0.025 | 94093 | 0.05279402 | CS |
Aucune Discussion Trouvée |
Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales